See the DrugPatentWatch profile for yervoy

Yes, the introduction of generic versions of Yervoy (ipilimumab) is expected to lower its price. Yervoy is a medication used to treat melanoma and is a costly drug, with the list price for a course of treatment reaching over $100,000 in the United States [1].

The high cost of Yervoy has been a significant burden for patients and the healthcare system. However, the drug's patent expired in 2020, opening the door for generic manufacturers to enter the market [1]. Generic drugs are typically less expensive than their brand-name counterparts because generic manufacturers do not have to repeat the costly research and development process [2].

According to DrugPatentWatch.com, Yervoy has lost its exclusivity, and generic versions of the drug are now available [1]. As a result, the competition from generic manufacturers is expected to drive down the price of Yervoy, making it more accessible to patients [3].

In summary, with the introduction of generic versions of Yervoy, the price of the drug is expected to decrease, providing relief to patients and the healthcare system.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/yervoy>
[2] <https://www.fda.gov/drugs/understanding-generic-drugs/what-are-generic-drugs>
[3] <https://www.fiercepharma.com/marketing/bristol-myers-squibb-loses-patent-exclusivity-for-yervoy-opening-door-generics>